VanEck Genomics and Healthcare Innovators UCITS ETF
| Issuer: Van Eck |
| Asset Class: Equity |
| TER: 25bps |
| Trading Currency: USD |
| Pays Income: False |
| Listing Date: 07 Sep 2022 |
| Ticker: CURE |
| ISIN: IE000B9PQW54 |
This investment provides targeted exposure to the transformative and rapidly advancing field of genomics and the broader healthcare sector. The core of the strategy lies in capturing the long-term growth potential of companies at the forefront of medical innovation. These firms are pioneering breakthroughs in areas such as gene editing, personalized medicine, targeted cancer therapies, and novel vaccines. By harnessing the power of genetic information, these companies are not just developing new treatments for once-intractable diseases but are also fundamentally changing how healthcare is delivered, making it more precise and effective. This focus on cutting-edge science offers a compelling narrative for growth-oriented investors.
The investment case is further strengthened by powerful, long-term secular tailwinds. A globally aging population, particularly in developed nations, is creating a sustained increase in demand for advanced healthcare solutions. Concurrently, rising wealth in emerging markets is expanding access to and spending on healthcare, opening up vast new markets for innovative companies. This fund concentrates on 'pure-play' companies that derive a significant portion of their revenue from the genomics and healthcare theme, ensuring a focused portfolio. Furthermore, the inclusion of an ESG screen enhances its appeal by excluding companies involved in controversial activities, aligning financial goals with sustainable investing principles.
By investing in a diversified basket of these leading-edge companies, investors can gain access to a high-growth segment of the global economy that is less correlated with traditional business cycles. It represents a strategic allocation for those looking to capitalize on the profound and lasting impact of scientific discovery on human health and longevity, backed by undeniable demographic trends.
